(Q30651564)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23799922%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

title

Safety and efficacy of different lanreotide doses in the treatment of polycystic liver disease: pooled analysis of individual patient data (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23799922%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

main subject

polycystic liver disease

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23799922%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

author name string

F Temmerman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23799922%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

T Gevers

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23799922%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

T A Ho

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23799922%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

R Vanslembrouck

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23799922%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

W Coudyzer

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23799922%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

J van Pelt

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23799922%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Y Pirson

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23799922%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

J P Drenth

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23799922%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

F Nevens

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23799922%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

language of work or name

English

0 references

publication date

25 June 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23799922%20AND%20SRC:MED&resulttype=core&format=json

Alimentary Pharmacology & Therapeutics

3 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23799922%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

volume

38

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23799922%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23799922%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

page(s)

397-406

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23799922%20AND%20SRC:MED&resulttype=core&format=json

Systematic review: the pathophysiology and management of polycystic liver disease

3 March 2020

cites work

1 reference

Polycystic liver: clinical characteristics of patients with isolated polycystic liver disease compared with patients with polycystic liver and autosomal dominant polycystic kidney disease.

21 January 2018

1 reference

Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases.

21 January 2018

1 reference

Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation

21 January 2018

1 reference

Liver transplantation for polycystic liver disease.

21 January 2018

1 reference

Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate.

21 January 2018

1 reference

Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease

21 January 2018

1 reference

Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease

21 January 2018

1 reference

Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide

21 January 2018

1 reference

Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel).

21 January 2018

1 reference

Accuracy of the MDRD (Modification of Diet in Renal Disease) study and CKD-EPI (CKD Epidemiology Collaboration) equations for estimation of GFR in the elderly

21 January 2018

1 reference

Somatostatin analog therapy for severe polycystic liver disease: results after 2 years

21 January 2018

1 reference

The long-term outcome of patients with polycystic liver disease treated with lanreotide.

21 January 2018

1 reference

Renal hemodynamic effects of somatostatin are not related to inhibition of endogenous insulin release

21 January 2018

1 reference

Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease.

21 January 2018

1 reference

A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly

21 January 2018

1 reference